Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
(Q40406835)
scientific article published on 8 July 2005
scientific article published on 8 July 2005
Language: